---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-031795"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:37:41.806260+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing

## Summary
- Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
- TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.
- Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.
- Cash ~$400M at end Q1 2026; no debt.
- Strategic Review Committee accelerating evaluation of alternatives including potential sale of company.

## SEC filing metadata
- accession: 0001104659-26-031795
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/0001104659-26-031795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/tm269321d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-031795
- JSON: https://secwatch.observer/filing/0001104659-26-031795.json
- Plain text: https://secwatch.observer/filing/0001104659-26-031795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.